Efficacy and tolerance of dorzolamide in patients with secondary inflammatory glaucoma associated with juvenile chronic arthritis: A 6-month follow-up study

Annals of Ophthalmology - Glaucoma

Volumn 31, Issue 6, 1999, Pages 329-332

  Assi, A ^a,b   Watts, P ^b  

^a MOORFIELDS EYE HOSPITAL   (United Kingdom)

^b KING EDWARD VII HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ACETAZOLAMIDE; DORZOLAMIDE;

ADOLESCENT; ADULT; ARTICLE; DISEASE ASSOCIATION; DRUG EFFICACY; DRUG TOLERABILITY; FEMALE; FOLLOW UP; HUMAN; JUVENILE RHEUMATOID ARTHRITIS; MALE; PRIORITY JOURNAL; SECONDARY GLAUCOMA; TREATMENT OUTCOME;

EID: 0032754430     PISSN: 10794794     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (6)

1. Kanski JJ. Juvenile arthritis and uveitis. Surv Ophthalmol. 1990; 34:253-267.
2. Cowan RA, Hartnell GG, Lowdell CP, et al. Metabolic acidosis induced by carbonic anhydrase inhibitors in patients with normal renal function. Br Med J. 1984;289:347-348.
3. Baldwin J, Ponticello G, Anderson P, et al. Thienothiopyran-2-sulfonamides: novel topically active carbonic anhydrase inhibitors for the treatment of glaucoma. J Med Chem. 1989;32:2510-2513.
4. Wang RF, Serle JB, Podos SM, Surgrue MF. MK-507 (L-671, 152), a topically active carbonic anhydrase inhibitor, reduces aqueous humor production in monkeys. Arch Ophthalmol. 1992;109;1297-1299.
5. Lippa EA, Carslon LE, Ehlinger B, et al. Dose response and duration of action of dorzolamide, a topical carbonic anhydrase inhibitor. Arch Ophthalmol. 1992;110:495-499.
6. Strahlman E, Tipping R. Vogel R, and the International Dorzolamide Study Group. A double-masked randomized 1-year study comparing dorzolamide (Trusopt), timolol, and betaxolol. Arch Ophthalmol. 1995;113:1009-1016.